{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T12:47:14Z","timestamp":1774442834801,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.bmc.2021.116438","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T07:27:58Z","timestamp":1632727678000},"page":"116438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Discovery of 1,8-naphthalidine derivatives as potent anti-hepatic fibrosis agents via repressing PI3K\/AKT\/Smad and JAK2\/STAT3 pathways"],"prefix":"10.1016","volume":"49","author":[{"given":"Zhen-Ning","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shang-Jiu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-Ning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Ke","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju-Xian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Wei","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2021.116438_b0005","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1177\/1756283X11413002","article-title":"Current status of novel antifibrotic therapies in patients with chronic liver disease","volume":"4","author":"Cohen-Naftaly","year":"2011","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.bmc.2021.116438_b0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.mam.2018.09.002","article-title":"Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues","volume":"65","author":"Parola","year":"2019","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.bmc.2021.116438_b0015","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.coph.2019.09.006","article-title":"New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseases","volume":"49","author":"Lemoinne","year":"2019","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.bmc.2021.116438_b0020","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3851\/IMP3327","article-title":"Long-term changes in hepatic fibrosis following hepatitis C viral clearance in patients with and without HIV","volume":"24","author":"Balmaceda","year":"2019","journal-title":"Antivir Ther"},{"key":"10.1016\/j.bmc.2021.116438_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0036-1597816","article-title":"Regression of Liver Fibrosis","volume":"37","author":"Campana","year":"2017","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.bmc.2021.116438_b0030","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.matbio.2017.11.002","article-title":"Inducible knockdown of procollagen I protects mice from liver fibrosis and leads to dysregulated matrix genes and attenuated inflammation","volume":"66","author":"Molokanova","year":"2018","journal-title":"Matrix Biol"},{"key":"10.1016\/j.bmc.2021.116438_b0035","first-page":"169","article-title":"Establishment and application of a high-throughput drug screening model based on COL1A1 promoter for anti-liver fibrosis","volume":"50","author":"Zhao","year":"2015","journal-title":"Yao Xue Xue Bao"},{"key":"10.1016\/j.bmc.2021.116438_b0040","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00042737-200402000-00001","article-title":"How can transforming growth factor beta be targeted usefully to combat liver fibrosis?","volume":"16","author":"Shek","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.bmc.2021.116438_b0045","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.apsb.2016.11.005","article-title":"A novel class of apical sodium\u2013dependent bile salt transporter inhibitors: 1-(2,4-bifluorophenyl)-7-dialkylamino-1,8-naphthyridine-3-carboxamides","volume":"7","author":"Liu","year":"2017","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"10.1016\/j.bmc.2021.116438_b0050","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.cclet.2016.07.024","article-title":"Synthesis and in vitro antitumor activity of novel naphthyridinone derivatives","volume":"28","author":"Jia","year":"2017","journal-title":"Chin Chem Lett"},{"key":"10.1016\/j.bmc.2021.116438_b0055","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejphar.2006.04.005","article-title":"Novel non-systemic inhibitor of ileal apical Na+-dependent bile acid transporter reduces serum cholesterol levels in hamsters and monkeys","volume":"539","author":"Kitayama","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bmc.2021.116438_b0060","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/hep.27973","article-title":"Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice","volume":"63","author":"Miethke","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.bmc.2021.116438_b0065","first-page":"305","article-title":"Design, synthesis, and evaluation of N-(3,5-difluorophenyl)-1-(alkoxyphenyl)-7-dimethylamino-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamides as inhibitors of ASBT","volume":"13","author":"Zhao","year":"2018","journal-title":"Chin Med Biotechnol"},{"key":"10.1016\/j.bmc.2021.116438_b0070","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/apt.13457","article-title":"The ileal bile acid transporter inhibitor A4250 decreases serum bile acids by interrupting the enterohepatic circulation","volume":"43","author":"Graffner","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bmc.2021.116438_b0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0218459","article-title":"Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-\/-.Leiden mice","volume":"14","author":"Salic","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bmc.2021.116438_b0080","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.matbio.2017.12.012","article-title":"Matrix metalloproteinases and liver fibrosis (translational aspects)","volume":"68\u201369","author":"Roeb","year":"2018","journal-title":"Matrix Biol J Int Soc Matrix Biol"},{"key":"10.1016\/j.bmc.2021.116438_b0085","first-page":"672","article-title":"Connective tissue growth factor binds to fibronectin through the type I repeat modules and enhances the affinity of fibronectin to fibrin","volume":"1770","author":"Yoshida","year":"2007","journal-title":"BBA"},{"key":"10.1016\/j.bmc.2021.116438_b0090","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.matbio.2018.03.007","article-title":"Connective tissue growth factor (CTGF) from basics to clinics","volume":"68\u201369","author":"Ramazani","year":"2018","journal-title":"Matrix Biol J Int Soc Matrix Biol"},{"key":"10.1016\/j.bmc.2021.116438_b0095","doi-asserted-by":"crossref","first-page":"384","DOI":"10.5603\/EP.2013.0022","article-title":"Transforming growth factor beta1 (TGFbeta1) in physiology and pathology","volume":"64","author":"Kajdaniuk","year":"2013","journal-title":"Endokrynologia Polska"},{"key":"10.1016\/j.bmc.2021.116438_b0100","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0945-053X(02)00055-0","article-title":"Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy?","volume":"21","author":"Blom","year":"2002","journal-title":"Matrix Biol J Int Soc Matrix Biol"},{"key":"10.1016\/j.bmc.2021.116438_b0105","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1146\/annurev.cellbio.21.022404.142018","article-title":"Specificity and versatility in tgf-beta signaling through Smads","volume":"21","author":"Feng","year":"2005","journal-title":"Annu Rev Cell Dev Biol"},{"key":"10.1016\/j.bmc.2021.116438_b0110","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41374-020-0425-4","article-title":"SPOCK1 overexpression induced by platelet-derived growth factor-BB promotes hepatic stellate cell activation and liver fibrosis through the integrin \u03b15\u03b21\/PI3K\/Akt signaling pathway","volume":"100","author":"Du","year":"2020","journal-title":"Lab Investig J Tech Methods Pathol"},{"key":"10.1016\/j.bmc.2021.116438_b0115","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/aps.2014.155","article-title":"The anti-fibrotic effects of epigallocatechin-3-gallate in bile duct-ligated cholestatic rats and human hepatic stellate LX-2 cells are mediated by the PI3K\/Akt\/Smad pathway","volume":"36","author":"Yu","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.bmc.2021.116438_b0120","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1074\/jbc.M306248200","article-title":"Activation of the pro-survival phosphatidylinositol 3-kinase\/AKT pathway by transforming growth factor-beta1 in mesenchymal cells is mediated by p38 MAPK-dependent induction of an autocrine growth factor","volume":"279","author":"Horowitz","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2021.116438_b0125","doi-asserted-by":"crossref","first-page":"7218","DOI":"10.1128\/MCB.21.21.7218-7230.2001","article-title":"Transforming growth factor beta1 (TGF-beta1) promotes endothelial cell survival during in vitro angiogenesis via an autocrine mechanism implicating TGF-alpha signaling","volume":"21","author":"Vi\u00f1als","year":"2001","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.bmc.2021.116438_b0130","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022137","article-title":"Signaling Cross Talk between TGF-\u03b2\/Smad and Other Signaling Pathways","volume":"9","author":"Luo","year":"2017","journal-title":"Cold Spring Harbor Perspect Biol"},{"key":"10.1016\/j.bmc.2021.116438_b0135","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1074\/jbc.M310412200","article-title":"The phosphatidylinositol 3-kinase\/Akt pathway enhances Smad3-stimulated mesangial cell collagen I expression in response to transforming growth factor-beta1","volume":"279","author":"Runyan","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2021.116438_b0140","doi-asserted-by":"crossref","first-page":"30708","DOI":"10.1074\/jbc.M113.478685","article-title":"Transforming growth factor-\u03b2 (TGF-\u03b2)-mediated connective tissue growth factor (CTGF) expression in hepatic stellate cells requires Stat3 signaling activation","volume":"288","author":"Liu","year":"2013","journal-title":"J Biol Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089621004466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089621004466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:15:21Z","timestamp":1760836521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089621004466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":28,"alternative-id":["S0968089621004466"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2021.116438","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of 1,8-naphthalidine derivatives as potent anti-hepatic fibrosis agents via repressing PI3K\/AKT\/Smad and JAK2\/STAT3 pathways","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2021.116438","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116438"}}